Literature DB >> 8725116

Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells.

M Haumont1, A Jacquet, M Massaer, V Deleersnyder, P Mazzu, A Bollen, P Jacobs.   

Abstract

The gene of the varicella-zoster virus (VZV) glycoprotein gE, engineered to code for a truncated molecule lacking the anchor and carboxy-terminal tail domains, was transfected into Chinese hamster ovary (CHO) cells via the pEE14 mammalian expression vector. One recombinant cell line, CHO-gE-2-9, secreted high levels of truncated gE into the culture medium. The product was purified to near homogeneity by a combination of anion exchange, hydrophobic and metal-chelate chromatographies. Purified recombinant gE showed the expected amino-terminal sequence and its glycosylation pattern proved similar to that of the natural product. When injected into mice, using either Freund's or alum as adjuvant, the native truncated gE induced complement-dependent neutralizing antibodies. In contrast, when the molecule was first denatured, it lost immunogenicity with alum. These data show that the recombinant gE, although truncated, could potentially be included in a subunit vaccine against VZV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725116     DOI: 10.1016/0168-1702(95)01270-2

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  12 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.

Authors:  Tehmina Bharucha; Damien Ming; Judith Breuer
Journal:  Hum Vaccin Immunother       Date:  2017-04-20       Impact factor: 3.452

3.  Efficacy of varicella (VZV) vaccination: an update for the clinician.

Authors:  Lili Wang; Lucy Zhu; Hua Zhu
Journal:  Ther Adv Vaccines       Date:  2016-01-01

4.  Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1.

Authors:  Anna Grahn; Marie Studahl; Staffan Nilsson; Elisabeth Thomsson; Malin Bäckström; Tomas Bergström
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

5.  Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.

Authors:  Yunfei Wang; Jialong Qi; Han Cao; Cunbao Liu
Journal:  Virol Sin       Date:  2020-08-05       Impact factor: 4.327

6.  Advances in animal cell recombinant protein production: GS-NS0 expression system.

Authors:  L M Barnes; C M Bentley; A J Dickson
Journal:  Cytotechnology       Date:  2000-02       Impact factor: 2.058

7.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

8.  Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.

Authors:  Su Jeen Lee; Hyo-Jung Park; Hae Li Ko; Jung Eun Lee; Hyun Joo Lee; Hun Kim; Jae-Hwan Nam
Journal:  Immun Inflamm Dis       Date:  2020-03-13

9.  Expression of variable viruses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using a novel plasmid based expression system in insect cell.

Authors:  A M Al-Sulaiman; P J Vallely; P E Klapper; Raid Al Baradie; Shaihana Abdulrahman Almatrrouk; Khalid K Alharbi
Journal:  Saudi J Biol Sci       Date:  2016-05-10       Impact factor: 4.219

10.  Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice.

Authors:  Han Cao; Yunfei Wang; Ning Luan; Cunbao Liu
Journal:  Vaccines (Basel)       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.